WHAT WAS DONE?

The hospital pharmacist is a permanent member of the lung cancer multidisciplinary team, which meets weekly since January 2016, to plan the management and treatment of lung cancer patients, in our hospital. The pharmacist brings updated information about efficacy and safety of drug treatments, its cost-effectiveness and its availability. The pharmacist improves the communication with the Pharmacy and Therapeutic Committee.

WHY WAS IT DONE?

Several clinical practice guidelines for lung cancer recommend that multidisciplinary teams should be used to plan patients’ treatment. The evolution of thoracic oncology, namely the increasing knowledge of the diverse histologic and molecular phenotypes in non-small cell lung cancer, has driven to more complex treatment algorithms in the recent years. This complexity increases the need for a multidisciplinary approach in therapeutic decision, which must be individualized and based on the best information available. The pharmacist inclusion in the multidisciplinary team is essential and was formerly proposed by the Pneumology Director to the Hospital Administration Board.

HOW WAS IT DONE?

The multidisciplinary team meets weekly to discuss the diagnose and treatment options of lung cancer patients, and includes a dedicated group of professionals: pulmonary oncologists, a thoracic surgeon, a radiation oncologist, a radiologist, a pathologist, a nuclear medicine specialist, a hospital pharmacist, a palliative care physician and an oncology nurse.

WHAT HAS BEEN ACHIEVED?

About 240 cases, corresponding to 200 patients are discussed per year. An average of 110 solicitations to the Pharmacy and Therapeutic Committee are made. The multidisciplinary team grants a systematic approach to diagnose and treatment, in compliance with evidence-based guidelines, improves communication and coordination between professionals and shorts waiting times for the patient.